SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Introgen Therapeutics
INGN 6.690-2.3%3:04 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: zeta1961 who wrote (697)3/29/2007 5:17:20 PM
From: JibacoaRead Replies (2) of 802
 
13-4 that it provides substantial evidence of efficacy..initially

Since you said that's the same panel taht is to consider ADVEXIN, Do you think that does increases INGN's chances for "conditional approval" ?<g>

Considering that:

The FDA has designated Fast Track Drug Product Development
program and Orphan Drug status for ADVEXIN in head and neck cancer.

ADVEXIN therapy is well tolerated and clinically active.

ADVEXIN therapy in recurrent head and neck cancer results in tumor responses and median survival that are comparable to the findings obtained with other more toxic therapies,& recurrent head and neck cancer patients with the abnormal p53 biomarker were most likely to have a survival benefit from ADVEXIN p53 therapy & were the least likely to benefit from conventional treatment.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News